 Connection
David Arciniegas to Central Nervous System Stimulants
This is a "connection" page, showing publications David Arciniegas has written about Central Nervous System Stimulants.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.066 |
|
|
|
-
Arciniegas DB, Seel RT, Macciocchi SN, Cifu DX, Frazier YG, Kaelin DL, Katz DI, Oyesanya TO, Wagner AK. Practice Guideline for Methylphenidate Use in Persons With Traumatic Brain Injury: Report of the American Congress of Rehabilitation Medicine. Arch Phys Med Rehabil. 2026 04; 107(4):753-760.
Score: 0.807
-
McDonald BC, Flashman LA, Arciniegas DB, Ferguson RJ, Xing L, Harezlak J, Sprehn GC, Hammond FM, Maerlender AC, Kruck CL, Gillock KL, Frey K, Wall RN, Saykin AJ, McAllister TW. Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial. Neuropsychopharmacology. 2017 Aug; 42(9):1766-1775.
Score: 0.108
-
Silver JM, McAllister TW, Arciniegas DB. Depression and cognitive complaints following mild traumatic brain injury. Am J Psychiatry. 2009 Jun; 166(6):653-61.
Score: 0.064
-
Arciniegas DB, Silver JM. Pharmacotherapy of posttraumatic cognitive impairments. Behav Neurol. 2006; 17(1):25-42.
Score: 0.051
-
Bridgeford D, Arciniegas DB, Batkis M, Sandberg E, Beresford TP. Methylphenidate treatment of neuropsychiatric symptoms of central and extrapontine myelinolysis. J Stud Alcohol. 2000 Sep; 61(5):657-60.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|